Modulation of adenylyl cyclase activity in young and adult rat brain cortex. Identification of suramin as a direct inhibitor of adenylyl cyclase

Journal of Cellular and Molecular Medicine

Volumn 9, Issue 4, 2005, Pages 940-952

  Stöhr, Jiri ^a,b   Novotny, Jiri ^a,b   Bourova, Lenka ^a,b   Svoboda, Petr ^a,b  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adenylyl cyclase activity; Dithiothreitol; Peroxidation; Rat brain cortex; Suramin

Indexed keywords

ANIMALIA;

EID: 30944467268     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2005.tb00390.x     Document Type: Article

References (58)

1. Mons N, Cooper DM. Adenylate cyclases: critical foci in neuronal signaling. Trends Neurosci. 1995; 18: 536-42.
2. Herrero I, Sanchez-Prieto J. cAMP-dependent facilitation of glutamate release by β-adrenergic receptors in cerebrocortical nerve terminals. J Biol Chem. 1996; 271: 30554-60.
3. Dohovics R, Janaky R, Varga V, Hermann A, Saransaari P, Oja SS. Regulation of glutamatergic neurotransmission in the striatum by presynaptic adenylyl cyclase-dependent processes. Neurochem Int. 2003; 42: 1-7.
4. Hurley JH. Structure, mechanism, and regulation of mammalian adenylyl cyclase. J Biol Chem. 1999; 274: 7599-602.
5. Patel TB, Du Z, Pierre S, Cartin L, Scholich K. Molecular biological approaches to unravel adenylyl cyclase signaling and function. Gene 2001; 269: 13-25.
6. Mons N, Harry A, Dubourg P, Premont RT, Iyengar R, Cooper DM. Immunohistochemical localization of adenylyl cyclase in rat brain indicates a highly selective concentration at synapses. Proc Natl Acad Sci USA. 1995; 92: 8473-7.
7. Matsuoka I, Suzuki Y, Defer N, Nakanishi H, Hanoune J. Differential expression of type I, II, and V adenylyl cyclase gene in the postnatal developing rat brain. J Neurochem. 1997; 68: 498-506.
8. Levitzki A, Bar-Sinai A. The regulation of adenylyl cyclase by receptor-operated G proteins. Pharmacol Ther. 1991; 50: 271-83.
9. Simonds WF. G protein regulation of adenylate cyclase. Trends Pharmacol Sci. 1999; 20: 66-73.
10. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol. 2001; 41: 145-74.
11. Desaubry L, Shoshani I, Johnson RA. Inhibition of adenylyl cyclase by a family of newly synthesized adenine nucleoside 3′-polyphosphates. J Biol Chem. 1996; 271: 14028-34.
12. Premont RT, Matsuoka I, Mattei MQ, Pouille Y, Defer N, Hanoune J. Identification and characterization of a widely expressed form of adenylyl cyclase. J Biol Chem. 1996; 271: 13900-7.
13. Ihnatovych I, Novotny J, Haugvicova R, Bourova L, Mares P, Svoboda P. Ontogenetic development of the G protein-mediated adenylyl cyclase signalling in rat brain. Brain Res Dev Brain Res. 2002; 133: 69-75.
14. Harden TK, Wolfe BB, Sporn JR, Perkins JP, Molinoff PB. Ontogeny of β-adrenergic receptors in rat cerebral cortex. Brain Res. 1977; 125: 99-108.
15. Keshles O, Levitzki A. The ontogenesis of β-adrenergic receptors and of adenylate cyclase in the developing rat brain. Biochem Pharmacol. 1984; 33: 3231-3.
16. Rius RA, Streaty RA, Peng Loh Y, Klee WA. Developmental expression of G proteins that differentially modulate adenylyl cyclase activity in mouse brain. FEBS Lett. 1991; 288: 51-4.
17. White AA. Separation and purification of cyclic nucleotides by alumina column chromatography. Methods Enzymol. 1974; 38: 41-6.
18. Baba A, Lee E, Ohta A, Tatsuno T, Iwata H. Activation of adenylate cyclase of rat brain by lipid peroxidation. J Biol Chem. 1981; 256: 3679-84.
19. Baba A, Kihara T, Lee E, Iwata H. Activation of rat brain adenylate cyclase by copper plus dithiothreitol. Biochem Pharmacol. 1981; 30: 171-4.
20. Oyama M, Kubota K. Inhibition by EDTA and enhancement by divalent cations or polyamines of the dithiothreitol-induced activation of adenylate cyclase in the cellular slime mold, Dictyostelium discoideum. Biochim Biophys Acta 1991; 1092: 85-8.
21. Schimke I, Haberland A, Will-Shahab L, Kuttner I, Papies B. Free radical-induced damage of cardiac sarcolemma (SL) and activity loss of β-receptor adenylate cyclase system (β-RAS). A comparison of the time courses. Biomed Biochim Acta 1989; 48: S69-72.
22. Schimke I, Haberland A, Will-Shahab L, Kuttner I, Papies B. In vitro effects of reactive O2 species on the beta-receptor-adenylyl cyclase system. Mol Cell Biochem. 1992; 110: 41-6.
23. Butler SJ, Kelly EC, McKenzie FR, Guild SB, Wakelam MJ, Milligan G. Differential effects of suramin on the coupling of receptors to individual species of pertussis-toxin-sensitive guanine-nucleotide-binding proteins. Biochem J. 1988; 251: 201-5.
24. Freissmuth M, Boehm S, Beindl W, Nickel P, Ijzerman AP, Hohenegger M, Nanoff C. Suramin analogues as subtype-selective G protein inhibitors. Mol Pharmacol. 1996; 49: 602-11.
25. Beindl W, Mitterauer T, Hohenegger M, Ijzerman AP, Nanoff C, Freissmuth M. Inhibition of receptor/G protein coupling by suramin analogues. Mol Pharmacol. 1996; 50: 415-23.
26. Ross EM, Hewlett AC, Ferguson KM, Gilman AG. Reconstitution of hormone-sensitive adenylate cyclase activity with resolved components of the enzyme. J Biol Chem. 1978; 253: 6401-12.
27. Tan CM, Kelvin DJ, Litchfield DW, Ferguson SS, Feldman RD. Tyrosine kinase-mediated serine phosphorylation of adenylyl cyclase. Biochemistry 2001; 40: 1702-9.
28. El-Mowafy AM, White RE. Evidence for a tyrosine kinase-dependent activation of the adenylyl Cyclase/PKA cascade downstream from the G-protein-linked endothelin ETA receptor in vascular smooth muscle. Biochem Biophys Res Commun. 1998; 251: 494-500.
29. Patrizio M, Slepko N, Levi G. Opposite regulation of adenylyl cyclase by protein kinase C in astrocyte and microglia cultures. J Neurochem. 1997; 69: 1267-77.
30. Tan CM, McDonald CG, Chorazyczewski J, Burry AF, Feldman RD, Macdonald CJ. Vanadate stimulation of adenylyl cyclase: an index of tyrosine kinase vascular effects. Clin Pharmacol Ther. 1999; 66: 275-81.
31. Suen ET, Kwan PC, Clement-Cormier YC. Selective effects of an essential sulfhydryl group on the activation of dopamine- and guanine nucleotide-sensitive adenylate cyclase. Mol Pharmacol. 1982; 22: 595-601.
32. Ozawa Y, Chopra IJ, Solomon DH, Smith F. The role of sulfhydryl groups in thyrotropin binding and adenylate cyclase activities of thyroid plasma membranes. Endocrinology 1979; 105:1221-5.
33. Skurat AV, Yurkova MS, Baranova LA, Gulyaev NN, Bulargina TV, Severin ES. Evidence for the existence of a sulfhydryl group in the adenylate cyclase active site. Biochem Int. 1985; 10:451-61.
34. Lin MC, Cooper DM, Rodbell M. Selective effects of organic mercurials on the GTP-regulatory proteins of adenylate cyclase systems. J Biol Chem. 1980; 255: 7250-4.
35. Murphy MG. Membrane fatty acids, lipid peroxidation and adenylate cyclase activity in cultured neural cells. Biochem Biophys Res Commun. 1985; 132:757-63.
36. Murphy MG. Studies of the regulation of basal adenylate cyclase activity by membrane polyunsaturated fatty acids in cultured neuroblastoma. J Neurochem. 1986; 47: 245-53.
37. Shin Y, White BH, Uh M, Sidhu A. Modulation of D1-like dopamine receptor function by aldehydic products of lipid peroxidation. Brain Res. 2003; 968: 102-13.
38. Coffey RJ Jr, Leof EB, Shipley GD, Moses HL. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol. 1987; 132: 143-8.
39. Mills GB, Zhang N, May C, Hill M, Chung A. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression. Cancer Res. 1990; 50:3036-42.
40. Minniti CP, Maggi M, Helman LJ. Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res. 1992; 52:1830-5.
41. Hensey CE, Boscoboinik D, Azzi A. Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett. 1989; 258: 156-8.
42. Mahoney CW, Azzi A, Huang KP. Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. Differential activation and inhibition of protein kinase C isozymes. J Biol Chem. 1990; 265: 5424-8.
43. Kopp R, Pfeiffer A. Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res. 1990; 50: 6490-6.
44. Schulze-Lohoff E, Bitzer M, Ogilvie A, Sterzel RB. P2U-purinergic receptor activation mediates inhibition of cAMP accumulation in cultured renal mesangial cells. Ren Physiol Biochem. 1995; 18:219-30.
45. Hall DA, Hourani SM. Effects of suramin on increases in cytosolic calcium and on inhibition of adenylate cyclase induced by adenosine 5′-diphosphate in human platelets. Biochem Pharmacol. 1994; 47: 1013-8.
46. Lopez-Lopez R, Langeveld CH, Pizao PE, van Rijswijk RE, Wagstaff J, Pinedo HM, Peters GJ. Effect of suramin on adenylate cyclase and protein kinase C. Anticancer Drug Des. 1994; 9: 279-90.
47. Jacobowitz O, Iyengar R. Phorbol ester-induced stimulation and phosphorylation of adenylyl cyclase 2. Proc Natl Acad Sci USA. 1994; 91:10630-4.
48. Watson PA, Krupinski J, Kempinski AM, Frankenfield CD. Molecular cloning and characterization of the type VII isoform of mammalian adenylyl cyclase expressed widely in mouse tissues and in S49 mouse lymphoma cells. J Biol Chem. 1994; 269: 28893-8.
49. Zimmermann G, Taussig R. Protein kinase C alters the responsiveness of adenylyl cyclases to G protein alpha and betagamma subunits. J Biol Chem. 1996; 271: 27161-6.
50. Lai HL, Lin TH, Kao YY, Lin WJ, Hwang MJ, Chern Y. The N terminus domain of type VI adenylyl cyclase mediates its inhibition by protein kinase C. Mol Pharmacol. 1999; 56: 644-50.
51. Kawabe J, Iwanii G, Ebina T, Ohno S, Katada T, Ueda Y, Homcy CJ, Ishikawa Y. Differential activation of adenylyl cyclase by protein kinase C isoenzymes. J Biol Chem. 1994; 269:16554-8.
52. s-stimulated adenylyl cyclases by phorbol ester treatment. J Biol Chem. 1993; 268: 3829-32.
53. Hadcock JR, Port JD, Gelman MS, Malbon CC. Cross-talk between tyrosine kinase and G-protein-linked receptors. Phosphorylation of β2-adrenergic receptors in response to insulin. J Biol Chem. 1992; 267: 26017-22.
54. Valiquette M, Parent S, Loisel TP, Bouvier M. Mutation of tyrosine-141 inhibits insulin-promoted tyrosine phosphorylation and increased responsiveness of the human β 2-adrenergic receptor. EMBO J. 1995; 14: 5542-9.
55. Ihnatovych I, Novotny J, Haugvicova R, Bourova L, Mares P, Svoboda P. Opposing changes of trimeric G protein levels during ontogenetic development of rat brain. Brain Res Dev Brain Res. 2002; 133: 57-67.
56. Stöhr J, Novotny J, Svoboda P. Characterization of [3H]forskolin binding sites in young and adult rat brain cortex. Identification of suramin as a competitive inhibitor of [3H]forskolin binding. Can J Physiol Pharmacol. 2005; 83: 573-81.
57. Summers ST, Walker JM, Sando JJ, Cronin MJ. Phorbol esters increase adenylate cyclase activity and stability in pituitary membranes. Biochem Biophys Res Commun. 1988; 151: 16-24.
58. Mikalsen SO, Kaalhus O. A characterization of pervanadate, an inducer of cellular tyrosine phosphorylation and inhibitor of gap junctional intercellular communication. Biochim Biophys Acta 1996; 1290: 308-18.